Michael Lofgren

Michael Lofgren is currently the Director of Preclinical Efficacy and Safety at Adaptimmune. Prior to this role, Michael held positions at TCR² Therapeutics Inc., Agenus, and 121 Bio, LLC, focusing on preclinical R&D, protein and cell sciences, and molecular biology. With a background in structural biology and protein enzymology, Michael has conducted research at Harvard Medical School and the University of Michigan, earning a PhD in Biological Chemistry. Additionally, Michael has experience in small molecule synthesis, microbiology, and materials science from roles at the University of Minnesota and 3M.